![]() Hepatic: Abnormal hepatobiliary function, increased serum alkaline phosphatase Hematologic & oncologic: Abnormal white blood cell differential, anemia, increased erythrocyte sedimentation rate, purpuric disease, thrombocytopenia Genitourinary: Dysuria, glycosuria, gynecological disease (dysmenorrhea, heavy menstrual bleeding, menstrual disease, spotty menstruation, uterine cramps), hematuria, impotence, mastalgia, urinary tract infection Gastrointestinal: Change in appetite, dysgeusia, dysphagia, gastroesophageal reflux disease, gastrointestinal hemorrhage, gastrointestinal infection, gastrointestinal inflammation, gingivitis, increased amylase, rectal disease Gastrointestinal: Constipation, dyspepsia, flatulence, nausea, vomitingĬardiovascular: Acute myocardial infarction, arterial thrombosis, cardiac arrhythmia, chest pain, edema, hypertension, hypotension, increased cardiac enzymes in blood specimen, phlebitis, pulmonary embolism, syncopeĭermatologic: Alopecia, dermatitis, diaphoresis, pallor, skin rashĮndocrine & metabolic: Increased thirst, loss of libido, weight changes >10%: Gastrointestinal: Abdominal pain, diarrhea (including severe diarrhea) The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Consult drug interactions database for more information. Data is insufficient to recommend use in patients with a prior cesarean delivery or transmural uterine scar ( Ref).ĭosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. ![]() ![]() May give an additional dose if placenta is not expelled 30 minutes after fetal expulsion. Patients 28 weeks’ gestation: 100 mcg vaginally, sublingually, or buccally every 6 hours. Vaginal administration should be avoided in patients with bleeding or signs of infection ( Ref). Termination of intrauterine pregnancy, monotherapy (off-label use): Note: Monotherapy may be used when mifepristone is not available however, misoprostol monotherapy is less effective ( Ref). Dosage ranges of 600 to 1,000 mcg as a single dose have been noted ( Ref), however, lower doses (200 to 400 mcg) may be sufficient as adjunctive therapy ( Ref). Use caution if a prophylactic dose was already given, especially if adverse events were observed ( Ref). Sublingual (off-label route): 800 mcg as a single dose. Rectal (off-label route): 600 to 1,000 mcg as a single dose ( Ref). Oral: 600 to 1,000 mcg as a single dose ( Ref) when used as adjunctive treatment, lower doses (200 to 400 mcg) may be sufficient ( Ref). Oral: 400 to 600 mcg as a single dose administered immediately after delivery ( Ref). Additional data may be necessary to further define the optimal dose and route of administration ( Ref).īuccal/sublingual (off-label route): 200 to 400 mcg as a single dose administered immediately after delivery (as adjunctive therapy with oxytocin) ( Ref). ![]() The risk of adverse reactions may be associated with combination therapy, dose, and/or route of administration. Note: Misoprostol as adjunctive therapy with oxytocin has been used in high-risk patients monotherapy is recommended in situations where oxytocin is not available (eg, resource-poor settings). In such patients, misoprostol may be prescribed if the patient has had a negative serum pregnancy test within 2 weeks prior to beginning therapy is capable of complying with effective contraceptive measures has received both oral and written warnings of the hazards of misoprostol, the risk of possible contraception failure, and the danger to other women of childbearing potential if the drug is taken by mistake and will begin misoprostol only on the second or third day of the next normal menstrual period. Misoprostol should not be used for reducing the risk of NSAID-induced ulcers in women of childbearing potential unless the patient is at high risk of complications from gastric ulcers associated with use of the NSAID, or is at high risk of developing gastric ulceration. Patients must be advised of the abortifacient property and warned not to give the drug to others. Misoprostol should not be taken by pregnant women to reduce the risk of ulcers induced by NSAIDs. The risk of uterine rupture increases with advancing gestational ages and with prior uterine surgery, including cesarean delivery. Uterine rupture has been reported when misoprostol was administered in pregnant women to induce labor or to induce abortion. Misoprostol administration to women who are pregnant can cause birth defects, abortion, premature birth, or uterine rupture.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |